Maria-Josefina Rivera
Family Medicine · Palatka, FLNPI 1780686881
Payments from drug & device makers
Across 191 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$616
- AstraZeneca$609
- AbbVie$481
- Novo Nordisk$422
- GSK$226
- Radius Health, Inc.$132
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,516100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 35 | $616 |
| AstraZeneca | 27 | $609 |
| AbbVie(2 entities) | 32 | $481 |
| Novo Nordisk | 32 | $422 |
| GSK | 7 | $226 |
| Radius Health, Inc. | 6 | $132 |
| Scilex Pharmaceuticals Inc. | 2 | $113 |
| Sanofi-aventis U.S. LLC | 6 | $107 |
| Bayer | 5 | $95 |
| Mylan Specialty L.p. | 4 | $93 |
| Amarin Pharma, Inc. | 5 | $82 |
| Abbott | 1 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $64 |
| Pfizer | 4 | $54 |
| Astellas Pharma US Inc | 3 | $54 |
| Johnson & Johnson | 3 | $41 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Exact Sciences | 2 | $33 |
| Merck | 2 | $28 |
| Catalyst Pharmaceuticals, Inc. | 1 | $25 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Eyevance Pharmaceuticals LLC | 1 | $21 |
| Emergent Biosolutions Inc. | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Insulet Corporation | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Amgen | 1 | $15 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$234
- TRELEGY ELLIPTA$100
How this compares
$3,516 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 79 | $123,663 |
| MounjaroTirzepatide | 77 | $120,069 |
| TrulicityDulaglutide | 53 | $73,015 |
| EliquisApixaban | 55 | $52,110 |
| FarxigaDapagliflozin Propanediol | 56 | $49,319 |
| LinzessLinaclotide | 36 | $45,711 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $36,875 |
| VascepaIcosapent Ethyl | 37 | $24,194 |
| OzempicSemaglutide | 17 | $22,140 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 34 | $19,328 |
| XareltoRivaroxaban | 15 | $17,308 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $13,409 |
| EntrestoSacubitril/Valsartan | 12 | $12,342 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $10,899 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $7,746 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $616 | $193,083130 claims |
| AbbVieVraylar, Linzess | $481 | $169,374115 claims |
| AstraZenecaFarxiga, Symbicort | $609 | $57,06567 claims |
| PfizerEliquis | $54 | $52,11055 claims |
| GSKTrelegy Ellipta | $226 | $36,87534 claims |
| MerckJanumet Xr, Janumet | $28 | $30,22850 claims |
| Novo NordiskOzempic | $422 | $22,14017 claims |
| Johnson & JohnsonXarelto | $41 | $17,30815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Palatka
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.